CBER Guidance Agenda Lists Two Trial-Related Documents Still to Come in 2022
July 29, 2022
The FDA’s Center for Biologics Evaluation and Research (CBER) has issued an updated agenda of guidances it intends to publish this year, indicating there are still two clinical research documents the center intends to address by the end of the year.